SPPI News and Press, Spectrum Pharmaceuticals Inc. From 03/21/19

The following slide deck was published by Spectrum Pharmaceuticals, Inc. in conjunction with this Read more ...

Spectrum Pharmaceuticals ( SPPI ) had to withdraw its Biologics License Application ((BLA)) of ROLONTIS after the FDA requested additional information. The information required doesn't call for any severe measures that will take years to fix; therefore, I believe that the biotech should be a...

Kopin (NASDAQ: KOPN )  -24%  on secondary offering . More news on: Kopin Corporation, PHI, Inc., Yield10 Bioscience, Inc., Stocks on the move, Read more ...

Agilent (NYSE: A ) initiated with Buy rating and $92 (14% upside) price target at UBS. More news on: Agilent Technologies, Inc., Amgen Inc., Fluidigm Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

Spectrum Pharmaceuticals (NASDAQ: SPPI ) is down  8%  premarket on light volume in response to its withdrawal of its U.S. marketing application seeking approval for ROLONTIS (eflapegrastim) for the management of chemo-induced neutropenia in patients undergoing myelosuppressive ch...

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI) announced today that due to the U.S. Food and Drug Administration’s (FDA) request for additional manufacturing-related information for ROLONTIS, the company has voluntarily withdrawn its Biologics License Application (BLA). Spectrum pla...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the Oppenheimer 29 th Annual Healthcare Conference bei...

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C., a step-down subsidiary of Aurobindo Pharm...

Spectrum Pharmaceuticals ( SPPI ) Q4 results : Revenues: $29.4M (+2.8%); Product sales: $28M (+0.4%); License fees and service revenue: $1.4M (+133.3%). More news on: Spectrum Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2018 Results Earnings Conference Call February 28, 2019, 04:30 PM ET Company Participants Shiv Kapoor - Vice President of Strategic Planning and Investor Relations Kurt Gustafson - Executive Vice President, Chief Financial Officer and Princi...